We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+7.36%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$496M
AUM Growth
+$20M
(+4.2%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
3.33%
Top 10 Holdings %
Top 10 Hldgs %
30.96%
Holding
92
New
31
Increased
21
Reduced
18
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stryker
SYK
|
+$13.3M |
| 2 |
Elevance Health
ELV
|
+$12.4M |
| 3 |
Revvity
RVTY
|
+$11.2M |
| 4 |
Biogen
BIIB
|
+$11.1M |
| 5 |
Humana
HUM
|
+$9.89M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$15.6M |
| 2 |
Cigna
CI
|
+$14.9M |
| 3 |
Universal Health Services
UHS
|
+$14.1M |
| 4 |
Intuitive Surgical
ISRG
|
+$11.7M |
| 5 |
Moderna
MRNA
|
+$10.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.57% |
| 2 | Consumer Staples | 0.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
76
Quest Diagnostics
DGX
$26.3B
| – | – |
-100,000
| Closed | -$15.6M |
|
77
Dianthus Therapeutics
DNTH
$6.17B
| – | – |
-26,000
| Closed | -$164K |
|
78
Doximity
DOCS
$4.51B
| – | – |
-131,000
| Closed | -$4.4M |
|
79
DaVita
DVA
$11.4B
| – | – |
-33,000
| Closed | -$2.46M |
|
80
Gilead Sciences
GILD
$170B
| – | – |
-120,000
| Closed | -$10.3M |
|
|
81
Intuitive Surgical
ISRG
$143B
| – | – |
-44,000
| Closed | -$11.7M |
|
82
Kymera Therapeutics
KYMR
$9.36B
| – | – |
-100,000
| Closed | -$2.5M |
|
83
PUT
Madrigal Pharmaceuticals
MDGL
$12.5B
| – | – |
-50,000
| Closed | -$14.5M |
|
84
Intellia Therapeutics
NTLA
$1.7B
| – | – |
-150,000
| Closed | -$5.23M |
|
85
Privia Health
PRVA
$2.75B
| – | – |
-130,000
| Closed | -$2.95M |
|
|
RAPT
86
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-13,625
| Closed | -$2.16M |
|
87
Sanofi
SNY
$104B
| – | – |
-200,000
| Closed | -$9.69M |
|
88
TG Therapeutics
TGTX
$7.64B
| – | – |
-150,000
| Closed | -$1.77M |
|
|
89
Universal Health Services
UHS
$9.98B
| – | – |
-100,000
| Closed | -$14.1M |
|
|
WBA
90
DELISTED
Walgreens Boots Alliance
WBA
| – | – |
-125,000
| Closed | -$4.67M |
|
91
Zimmer Biomet
ZBH
$18.3B
| – | – |
-65,000
| Closed | -$8.29M |
|
|
NVRO
92
DELISTED
NEVRO CORP.
NVRO
| – | – |
-109,000
| Closed | -$4.32M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q1 2023 Portfolio in Review
As of Q1 2023, Integral Health Asset Management held 92 positions worth $496M, up 4.2% from $476M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Integral Health Asset Management deployed $16.5M of net new capital in Q1 2023, opening 31 new positions and adding to 21 existing holdings. Its largest new stake was Stryker: 50,000 shares worth $14.3M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 93% a quarter earlier, followed by Consumer Staples.
On the sell side, the largest reduction was Moderna, an estimated $10.7M trimmed.
- Integral Health Asset Management's largest Q1 2023 buy was Stryker: 50,000 shares worth $14.3M.
- Integral Health Asset Management added most to Elevance Health in Q1 2023, an estimated $12.4M increase.
- Integral Health Asset Management's biggest Q1 2023 reduction was Moderna, cutting an estimated $10.7M.
- Integral Health Asset Management fully exited Quest Diagnostics in Q1 2023, selling an estimated $15.6M.
- Integral Health Asset Management's ten largest holdings make up 31% of its $496M portfolio in Q1 2023.
- Integral Health Asset Management opened 31 new positions and closed 21 in Q1 2023.
- Integral Health Asset Management's portfolio value rose 4.2% quarter-over-quarter to $496M.
Based on Integral Health Asset Management's 13F filing for Q1 2023, filed 9 May 2023.